Nuvectis Pharma
NVCT
37 hedge funds and large institutions have $20M invested in Nuvectis Pharma in 2023 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 2 closing their positions.
1,250% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 2
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
216% more capital invested
Capital invested by funds: $6.34M → $20M (+$13.7M)
208% more funds holding
Funds holding: 12 → 37 (+25)
4.63% more ownership
Funds ownership: 3.19% → 7.83% (+4.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.8M |
| 2 |
State Street
Boston,
Massachusetts
|
+$1.47M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.24M |
| 4 |
JMFC
J.M. Forbes & Co
Boston,
Massachusetts
|
+$1.07M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BWP
Baldwin Wealth Partners
Marion,
Massachusetts
|
-$858K |
| 2 |
Millennium Management
New York
|
-$323K |
| 3 |
Jane Street
New York
|
-$145K |
| 4 |
EDRH
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
-$27.9K |
NVCT Hedge Fund Activity: Q2 2023 in Review
37 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Nuvectis Pharma (NVCT) for Q2 2023, worth a combined $20M — up 216% from $6.34M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new NVCT positions and 2 closed out — a net gain of 25 holders — while 8 added to existing stakes and 2 trimmed.
The largest buyer was BlackRock, adding an estimated $4.8M. The largest seller was Baldwin Wealth Partners, cutting an estimated $858K.
- 37 institutional investors held Nuvectis Pharma (NVCT) as of Q2 2023, up from 12 in Q1 2023.
- Funds reported $20M of Nuvectis Pharma stock for Q2 2023, up 216% quarter-over-quarter.
- 27 funds opened new Nuvectis Pharma positions in Q2 2023 and 2 closed out, a net change of +25 holders.
- The largest Nuvectis Pharma buyer in Q2 2023 was BlackRock, an estimated $4.8M added.
- The largest Nuvectis Pharma seller in Q2 2023 was Baldwin Wealth Partners, an estimated $858K sold.
Based on aggregated 13F filings for Q2 2023.